导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.31% | 2045/4700 |
| 近一周 | -0.55% | 1111/5371 |
| 近一月 | 1.16% | 341/5328 |
| 近一季 | 1.60% | 685/5140 |
| 近半年 | -2.52% | 2124/4839 |
| 近一年 | 3.33% | 2063/4338 |
| 近两年 | 25.44% | 2451/2925 |
| 近三年 | 27.16% | 1192/2229 |
| 成立以来 | 93.71% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.35% 958/4961 |
-8.27% 3868/5312 |
- - |
- - |
| 2025 | 2.33% 3191/4813 |
-1.68% 2738/3635 |
3.12% 1151/4076 |
-1.92% 3970/4524 |
2.90% 816/4813 |
| 2024 | 29.45% 130/3463 |
10.49% 56/2808 |
3.58% 264/3014 |
10.94% 2577/3129 |
1.95% 1001/3463 |
| 2023 | 14.71% 42/2656 |
11.06% 351/2280 |
6.00% 53/2385 |
2.54% 228/2515 |
-4.97% 1223/2655 |
| 2022 | -3.81% 73/2207 |
-1.32% 143/1919 |
-1.33% 1708/2016 |
-4.67% 58/2113 |
3.63% 666/2208 |
| 2021 | 17.35% 235/1822 |
10.49% 36/1255 |
-0.61% 1144/1330 |
7.54% 181/1466 |
-0.63% 1262/1822 |
| 2020 | - - |
- - |
-0.65% 1023/1067 |
9.76% 626/1164 |
5.25% 796/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 南方红利低波50ETF联接A VS. 长安沪深300非周期A(740101) |